Journal of Public Health International

Open Access - Peer-Reviewed - ISSN 2641-4538

Portico Archived | Crossref DOI | CC BY 4.0 Licensed

Commentary

Questioning Success in Pediatric Hodgkin Lymphoma

Pedro Zubizarreta [1*]

[1] Hospital de Pediatría Garrahan, Argentina

*** Correspondence:** Pedro Zubizarreta, Hospital de, Pediatría, Garrahan, Argentina

Published citation: Pedro Zubizarreta (2022) **Questioning Success in Pediatric Hodgkin Lymphoma**. *Journal of Public Health International* - 6(2):18-20. https://doi.org/10.14302/issn.2641-4538.jphi-22-4369

Article DOI: 10.14302/issn.2641-4538.jphi-22-4369

Abstract

An opinion revisits definitions of success in pediatric Hodgkin lymphoma, balancing survival metrics with late effects and quality of life to inform patient-centered care.

Keywords:
adolescent; paediatric; treatment; cardiovascular

Article Information	
Academic Editor	Anubha Bajaj, Consultant Histopathology, A.B. Diagnostics, New Delhi, India
Received Date	8 November 2022
Accepted Date	25 November 2022
Published Date	9 December 2022
Online	9 December 2022
Publication	Volume 6; Issue 2; Pages 18–20
Copyright	© 2022 Pedro Zubizarreta
License	This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. https://creativecommons.org/licenses/by/4.0/

Commentary

Hodgkin Lymphoma (HL) is considered a highly curable malignant paediatric disease with an overall 5-year survival over 95%.

Surviving adolescent and child patients face a future of many decades of life with an increasing risk of late sequelae that will appear in the long run. A 5-year follow-up will not show adequately late therapy related morbidity and mortality.

The risk of morbidity and premature mortality by secondary malignant diseases, cardiovascular disease, lung disease and other chronic conditions stays significantly high in paediatric survivors followed more than 10 years.

Current paediatric HL treatment trials have highlighted the importance of diminishing acute and long term toxicity, but radiotherapy, though with lower doses and field restrictions, has been included in the schedules even for early stage cases until recently.

A recent publication reported the analysis of excess of deaths in paediatric survivors with HL compared with normal general population. An important incidence of cardiovascular disease and secondary neoplasia led to an increasing number of premature deaths that even overcame the initial disease-free survival benefits of new therapies [1].

With 500 randomized patients, CCG/COG 5942 Trial showed no significant 10-year survival results between patients who attained complete remission and were administered additional radiotherapy compared with those who were not [2]. Other studies showed similar results in terms of avoiding RT [3,4,5].

However, not using radiotherapy at all when achieving CR with chemotherapy had a surprising resistance in paediatric leading groups. Radiotherapy had been culturally judged as indispensable to treat HL, but at the same time a strange negation of the evidence, even that produced by COG5942 Trial, was installed.

Paediatric oncologists stand subjectively away from events that will appear in adulthood. Besides, the race to publish successful results in the short run does not permit to assume the risk of a “draw-back” in event free survival, no matter how small it could be.

Currently, big trials such as Euro Net-PHL (NCT02684708) or small ones such as GALOP 2017 (NCT03500133) are engaged to avoid radiotherapy in paediatric HL good responders to chemotherapy.

With successful results of these trials avoiding radiotherapy, we will finally be true when we say that HL is curable in the long term.

Competing Interests

The authors have declared that no competing interests exist.

References

1. Williams A, Liu Q, Bhakta N, Krull K, Hudson M, RobinsonL, Yasui Y. Rethinking success in Pediatric Oncology: Beyond 5-year survival. 2021. *J Clin Oncol*, 39:2227-31. https://doi.org/10.1200/jco.20.03681
2. Wolden S L, Chen L, Kelly K M. Long term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma: A report from the Children’s Oncology Group. 2012. *J Clin Oncol*, 30: 3174-3180. https://doi.org/10.1200/jco.2011.41.1819
3. Zubizarreta P, Alfaro E, Guitter M, C Sánchez La Rosa, Galluzzo M L. 2017. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy. J Pediatr Hematol Oncol;39: 602-608. https://doi.org/10.1097/mph.0000000000000943
4. Vecchi V, Pileri S, Burnelli R. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age: An Italian (AIEOP) multicenter study on 215 patients. 1993. *Cancer*, 72:2049-2057. https://doi.org/10.1002/1097-0142(19930915)72:6<2049::aid-cncr2820720642>3.0.co;2-v

5. Castellanos E M, Barrantes J C, Baez LF A. chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: 1999. *AHOPCA LH. Pediatr Blood Cancer*, 61:997-1002

Publisher's Note

All claims, opinions, data, and conclusions expressed in this article are solely those of the author(s) and contributor(s), and do not necessarily represent those of Open Access Pub, the journal, its editors, or reviewers. Open Access Pub does not guarantee or endorse any product, method, instruction, or claim discussed in the article, and disclaims responsibility for any injury to people or property resulting from ideas, methods, instructions, or products referred to in the content.